Global Glaucoma Therapeutics Market 2014-2018


◆タイトル:Global Glaucoma Therapeutics Market 2014-2018
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:pdf / 英語
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥308,000見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About Glaucoma Therapeutics
Glaucoma is a disease of the eye in which fluid pressure within the eye increases. If left untreated the patient may lose vision and even become blind. The exact etiology of optic nerve damage due to glaucoma is not fully known, but involves mechanical compression and/or decreased blood flow in the optic nerve. Based on whether the cause of the disease is unknown or known, glaucoma is divided into two types, open angle and closed angle glaucoma. Five main classes of medical treatment are currently used to lower intraocular pressure: prostaglandins, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, and fixed dose combinations.
TechNavio’s analysts forecast the Global Glaucoma Therapeutics market will grow at a CAGR of 2.53 percent over the period 2013-2018.
Covered in this Report
The Global Glaucoma Therapeutics market can be divided into five segments: Prostaglandins, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, and Fixed Dose Combinations. To calculate the market size, the report considers the revenue generated from the sales of various ophthalmic solutions used in the treatment of glaucoma. TechNavio’s report, the Global Glaucoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Glaucoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
Key Vendors
• Allergan Inc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
Other Prominent Vendors

• Acadia Pharmaceuticals Inc.
• AC Immune SA
• Acorn Biomedical Inc.
• Advanced Cell Technology Inc.
• Aerie Pharmaceuticals Inc.
• Carl Zeiss Meditec Inc.
• Falcon Pharmaceuticals Ltd.
• Inotek Pharmaceuticals Corp.
• Lexicon Pharmaceuticals Inc.
• Neurotech Pharmaceuticals Inc.
• NicOx SA
• Otsuka Holdings Co. Ltd.
• Phytopharm plc
• Santen Pharmaceuticals Co. Ltd.
• Senju Pharmaceutical Co. Ltd.
• Valeant Pharmaceuticals International Inc.
Key Market Driver
• Increasing Prevalence of Eye Disorders.
• For a full, detailed list, view our report.
Key Market Challenge
• Increasing Number of Patent Expirations.
• For a full, detailed list, view our report.
Key Market Trend
• Increase in Awareness of Glaucoma.
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Glaucoma Therapeutics Market in the US
06.3.1 Market Size and Forecast
06.4 Glaucoma Therapeutics Market in the Europe
06.4.1 Market Size and Forecast
06.5 Glaucoma Therapeutics Market in Japan
06.5.1 Market Size and Forecast
06.6 Five Forces Analysis
07. Pipeline Snapshot
08. Rate of Incidence and Prevalence
08.1.1 US
08.1.2 UK
08.1.3 Spain
08.1.4 Germany
08.1.5 Japan
09. Market Segmentation by Drug Class
10. Geographical Segmentation
10.1 Glaucoma Therapeutics Market in the Americas
10.1.1 Market Size and Forecast
10.2 Glaucoma Therapeutics Market in the EMEA Region
10.2.1 Market Size and Forecast
10.3 Glaucoma Therapeutics Market in the APAC Region
10.3.1 Market Size and Forecast
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Allergen Inc.
19.1.1 Business Overview
19.1.2 Business Segmentation
19.1.3 Key Information
19.1.4 SWOT Analysis
19.2 Merck & Co. Inc.
19.2.1 Business Overview
19.2.2 Business Segmentation
19.2.3 Key Information
19.2.4 SWOT Analysis
19.3 Novartis A.G.
19.3.1 Business Overview
19.3.2 Business Segmentation
19.3.3 Key Information
19.3.4 SWOT Analysis
19.4 Pfizer Inc.
19.4.1 Business Overview
19.4.2 Business Segmentation
19.4.3 Key Information
19.4.4 SWOT Analysis
20. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Glaucoma Therapeutics Market 2013-2018 (US$ billion)
Exhibit 3: Glaucoma Therapeutics Market in the US 2013-2018 (US$ billion)
Exhibit 4: Glaucoma Therapeutics Market in the Europe 2013-2018 (US$ billion)
Exhibit 5: Glaucoma Therapeutics Market in Japan 2013-2018 (US$ billion)
Exhibit 6: Global Glaucoma Therapeutics Market Segmentation by Drug Class
Exhibit 7: Global Glaucoma Therapeutics Market Segmentation 2013
Exhibit 8: Global Glaucoma Therapeutics Market by Geographical Segmentation 2013
Exhibit 9: Glaucoma Therapeutics Market in the Americas 2013-2018 (US$ billion)
Exhibit 10: Glaucoma Therapeutics Market in the EMEA region 2013-2018 (US$ billion)
Exhibit 11: Glaucoma Therapeutics Market in the APAC region 2013-2018 (US$ billion)
Exhibit 12: Global Glaucoma Therapeutics Market by Vendor Segmentation 2013
Exhibit 13: Business Segmentation of Allergen Inc.
Exhibit 14: Business Segmentation of Merck & Co. Inc.
Exhibit 15: Business Segmentation of Novartis A.G.
Exhibit 16: Business Segmentation of Pfizer Inc.


Allergan Inc. ,Merck & Co. Inc. ,Novartis AG ,Pfizer Inc.,Acadia Pharmaceuticals Inc.,AC Immune SA ,Acorn Biomedical Inc.,Advanced CellTechnology Inc.,Aerie Pharmaceuticals Inc.,Carl Zeiss Meditec Inc.,Falcon Pharmaceuticals Ltd.,Inotek Pharmaceuticals Corp.,LexiconPharmaceuticals Inc.,Neurotech Pharmaceuticals Inc. ,NicOx SA,Otsuka Holdings Co. Ltd.,Phytopharm plc,SantenPharmaceuticals Co. Ltd.,Senju Pharmaceutical Co. Ltd.,SIFI SpA,Valeant Pharmaceuticals International Inc.